Stock Track | Summit Therapeutics Soars 11.46% on Positive Ivonescimab Lung Cancer Trial Results

Stock Track

06/01

Summit Therapeutics PLC (SMMT) experienced a significant surge of 11.46% in pre-market trading on Monday, following the release of promising clinical trial data for its investigational drug ivonescimab.

The sharp increase in the stock price is attributed to the company's presentation of Phase 3 HARMONi-6 trial results at the ASCO 2026 conference. The data showed that ivonescimab, a PD-1/VEGF bispecific antibody, combined with chemotherapy, met the prespecified interim overall survival endpoint for first-line advanced squamous non-small cell lung cancer (NSCLC).

Earlier interim results from the trial, which enrolled 532 patients, demonstrated a median progression-free survival of 11.1 months for the ivonescimab group versus 6.9 months for the control group, with a hazard ratio of 0.60. The positive survival data for the drug, which is approved in China and investigational elsewhere, has generated significant investor optimism regarding its potential market success.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1128280885"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128280885\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128280885?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 15:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128280885","market":"sg","top_or_hot":-1,"title":"Stock Track | Summit Therapeutics Soars 11.46% on Positive Ivonescimab Lung Cancer Trial Results","media":"Stock Track","content":"<p>Summit Therapeutics PLC (SMMT) experienced a significant surge of 11.46% in pre-market trading on Monday, following the release of promising clinical trial data for its investigational drug ivonescimab.</p><p>The sharp increase in the stock price is attributed to the company's presentation of Phase 3 HARMONi-6 trial results at the ASCO 2026 conference. The data showed that ivonescimab, a PD-1/VEGF bispecific antibody, combined with chemotherapy, met the prespecified interim overall survival endpoint for first-line advanced squamous non-small cell lung cancer (NSCLC).</p><p>Earlier interim results from the trial, which enrolled 532 patients, demonstrated a median progression-free survival of 11.1 months for the ivonescimab group versus 6.9 months for the control group, with a hazard ratio of 0.60. The positive survival data for the drug, which is approved in China and investigational elsewhere, has generated significant investor optimism regarding its potential market success.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Summit Therapeutics Soars 11.46% on Positive Ivonescimab Lung Cancer Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Summit Therapeutics Soars 11.46% on Positive Ivonescimab Lung Cancer Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-01 15:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Summit Therapeutics PLC (SMMT) experienced a significant surge of 11.46% in pre-market trading on Monday, following the release of promising clinical trial data for its investigational drug ivonescimab.</p><p>The sharp increase in the stock price is attributed to the company's presentation of Phase 3 HARMONi-6 trial results at the ASCO 2026 conference. The data showed that ivonescimab, a PD-1/VEGF bispecific antibody, combined with chemotherapy, met the prespecified interim overall survival endpoint for first-line advanced squamous non-small cell lung cancer (NSCLC).</p><p>Earlier interim results from the trial, which enrolled 532 patients, demonstrated a median progression-free survival of 11.1 months for the ivonescimab group versus 6.9 months for the control group, with a hazard ratio of 0.60. The positive survival data for the drug, which is approved in China and investigational elsewhere, has generated significant investor optimism regarding its potential market success.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"","article_id":"1128280885","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128280885","pubTimestamp":1780299350,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Summit Therapeutics PLC (SMMT) experienced a significant surge of 11.46% in pre-market trading on Monday, following the release of promising clinical trial data for its investigational drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMMT":"Summit Therapeutics PLC"},"translate_title":"股票追踪|Summit Therapeutics因Ivonescimab肺癌试验结果积极飙升11.46%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1},"content_text":"Summit Therapeutics PLC (SMMT) experienced a significant surge of 11.46% in pre-market trading on Monday, following the release of promising clinical trial data for its investigational drug ivonescimab.The sharp increase in the stock price is attributed to the company's presentation of Phase 3 HARMONi-6 trial results at the ASCO 2026 conference. The data showed that ivonescimab, a PD-1/VEGF bispecific antibody, combined with chemotherapy, met the prespecified interim overall survival endpoint for first-line advanced squamous non-small cell lung cancer (NSCLC).Earlier interim results from the trial, which enrolled 532 patients, demonstrated a median progression-free survival of 11.1 months for the ivonescimab group versus 6.9 months for the control group, with a hazard ratio of 0.60. The positive survival data for the drug, which is approved in China and investigational elsewhere, has generated significant investor optimism regarding its potential market success.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}